Jeff Behrens, MS, MBA – President and CEO, Board of Directors
Jeff joined Siamab Therapeutics in May 2012. From 2009 to 2012, he served as Senior Director of Business Development & Operations for Edimer Pharmaceuticals, a Third Rock-funded orphan drug company, where he oversaw manufacturing, finance, business development, and academic research collaborations. Prior to Edimer, Jeff worked at Alnylam as Director, Strategic Alliances and at Biogen Idec as co-founder and Head of Business Operations at the Biogen Idec Innovation Incubator. Jeff has an MBA from MIT Sloan and a MS from the joint Harvard/MIT Division of Health Sciences and Technology. Jeff was previously the founder and CEO of The Telluride Group, a Newton, MA based managed services IT provider to the healthcare industry that was sold to mindSHIFT Technologies (funded by Fidelity) in 2003.

Julie Hermann, MS, MBA – Senior Director, Corporate Development
Julie joined Siamab Therapeutics in September 2012, and manages business development, finance, program management, and operations for the company. Prior to Siamab, Julie held various positions in strategy and operations management at Frankel Group, McKinsey & Company, Amgen, and Cerner Corporation. Julie has an MBA from MIT Sloan and a MS from the joint Harvard/MIT Division of Health Sciences and Technology.

Kristan Meetze, PhD – Senior Director, R&D
Kristan joined Siamab Therapeutics in July 2014 and leads Siamab's scientific development. Prior to joining Siamab, Kristan served as the Head of Biology at Blend Therapeutics. Prior to Blend, Kristan served as Associate Director at AVEO Pharmaceuticals where she oversaw the pharmacology and preclinical development of AVEO’s antibody pipeline. Previously, Kristan also served in scientific roles of increasing responsibility at both Millennium Pharmaceuticals and Eli Lilly & Co. Kristan received her PhD in cancer biology from Wayne State University in Michigan.

Ana Paula Galvao da Silva, PhD – Senior Research Scientist
Ana joined Siamab Therapeutics in June 2013. Prior to joining Siamab, Ana was a postdoc fellow in immunology at Stanford University, and a research scientist at Tocagen and AnaptysBio, where she led the discovery efforts of four monoclonal antibodies in preclinical development. She completed her Bachelors at Federal University of Pernambuco, Brazil, and doctorate at University of São Paulo, Brazil.

Mai Zhang, MD, PhD – Senior Research Scientist
Mai joined Siamab Therapeutics in August 2010. Prior to Siamab, Mai also was a post-doc fellow at Johnson & Johnson, where she worked on histamine H4 receptor and its function on immune diseases, and a research scientist at Nexbio, where she worked on drug discovery projects including a flu therapeutic targeting sialic acid. She received her medical degree in China, and then pursued her PhD degree at the University of California, San Diego in Biomedical Sciences. At UCSD, Mai studied the effects of sialic acid and the receptors in the immune system in Dr. Ajit Varki’s lab. .

Ajit Varki, MD - Co-Founder, Board of Directors
Dr. Varki is currently the Distinguished Professor of Medicine and Cellular and Molecular Medicine, and Co-Director of the Glycobiology Research and Training Center at UCSD. Dr. Varki received basic training in physiology, medicine, biology, and biochemistry at the Christian Medical College, Vellore, The University of Nebraska, and Washington University in St. Louis. He also has formal training and certification in internal medicine, hematology, and oncology. Dr. Varki’s research interests include the role of sialic acids in viral and bacterial infections, regulation of the immune response, initiation and progression of tumors, and unique aspects of human evolution.

Sundar Subramaniam, MS, MBA – Board of Directors
Sundar Subramaniam is Chairman of IBCC, whose holdings include Cambridge Technology Enterprises, Knome, MTPV, Cambridge Energy Resources, ThriveHive and DNSstuff. He is Chairman of Knome and Sialix and General Partner at Higher Moment Capital. He previously served as Chairman of I-Cube, C-bridge, Open Environment Corporation, and OneWave – all of which completed IPO’s and Answerfriend (Inquira, acq Oracle), WorldStreet (acq Thomson Reuters) and Integrated Computing Engines (acq Media100), director of DNSstuff (acq Solarwinds) and Managing Partner of Cambridge Samsung Partners, a Venture Capital firm.

Brad Curley, BS, CPA - Board of Directors
Brad Curley is a member of Boston Harbor Angels and an adjunct professor at Boston College. He was with KPMG LLP for more than 25 years providing services to clients in many industries. Brad was Partner in Charge of KPMG’s New England Area Internal Audit, Risk and Compliance Services practice and also served as the Firm’s Advisory Services practice leader for Northeast Area middle market accounts. He is a member of Board Leaders, the Corporate Directors Group and the National Association of Corporate Directors.